Antitrust Antitrust

Juno, Natco, Celgene withdraw Australian antitrust authorization request for patent settlement

By Laurel Henning
  • 29 Jul 2022 05:27
  • 29 Jul 2022 05:27
Bristol Myers Squibb subsidiary Celgene, along with Australia’s Juno and India’s Natco Pharma, have withdrawn an application for Australia’s competition regulator to authorize the companies’ patent-settlement deal.
In a letter today to the Australian Competition & Consumer Commission, or ACCC, the companies withdrew the application with immediate effect, giving no

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Laurel Henning

Senior Correspondent

Laurel is a senior correspondent specializing in competition law, data privacy and security, in Australia and New Zealand. Laurel reports from Sydney on criminal-cartel legislation and white-collar crime, as well as competition and consumer lawsuits involving companies including Google, Meta Platforms and Apple. While at MLex Laurel has also reported boardroom disputes and shareholder campaigns agitating for changes to company strategy. Laurel joined MLex in 2013 and reported for five years on European energy and climate policies from Brussels. In that time, Laurel covered the regulation of emissions and technological developments pertaining to the energy sector within the EU, as well as the Paris agreement in 2015. A graduate of the University of Liverpool, Laurel studied English and French before beginning a career in journalism with MLex.

Discover MLex

Stay on top of global regulatory developments

Latest News